Apo A

Note: this site is for informational purposes only. To view test results or book a test, use the NHS app in England or contact your GP.

The apo (apolipoprotein) test is a blood test in which a sample is drawn from a vein to measure levels of apolipoproteins, the protein components of lipoprotein particles. It is used to assess cardiovascular risk by helping to evaluate lipid metabolism and the likelihood of atherosclerotic disease.

Formal name 
Apolipoprotein A‑I

Why get tested?

To determine whether or not you have adequate levels of apo A‑I, to diagnose people with specific apo A deficiency and to help determine your risk of developing coronary heart disease (CHD).

When to get tested?

This is not a routinely performed test and is currently limited to hospital specialists, and specialist testing laboratories. It can be measured when you have hyperlipidaemia and/​or a family history of CHD or peripheral vascular disease; when your doctor is trying to assess your risk of developing heart disease; when apo A deficiency is suspected and when you are monitoring the effectiveness of lipid treatment and/​or lifestyle changes.

Sample required?

Typically, a blood sample is obtained by inserting a needle into a vein in your arm. As an alternative, particularly in paediatric care, the blood sample is taken from the fingertip.

Test preparation needed?

No test preparation is needed; however, since this test may be performed at the same time as a lipid profile, fasting for at least 12 hours may be required.

What is being tested?

Apolipoproteins are the protein component of lipoproteins – complexes that transport lipids throughout the bloodstream. Apolipoproteins provide structural integrity to lipoproteins and shield the hydrophobic (water repellent) lipids at their centre.

Most lipoproteins are cholesterol- or triglyceride-rich and carry lipids throughout the body, for uptake by cells. High-density lipoprotein (HDL – also known as good” cholesterol), however, is like an empty taxi. It goes out to the tissues and picks up excess cholesterol, then transports it back to the liver. In the liver the cholesterol is either recycled for future use or excreted into bile. HDL’s reverse transport is the only way that cells can get rid of excess cholesterol.

Apolipoprotein A is the taxi driver. It activates the enzymes that load cholesterol from the tissues into HDL and allows HDL to be recognised and bound by receptors in the liver at the end of the transport. There are two forms of apolipoprotein A, apo A‑I and apo A‑II. Apo A‑I is found in greater proportion than apo A‑II (about 3 to 1). The concentration of apo A‑I can be measured directly, unlike HDL, and tends to rise and fall with HDL levels. This has led some experts to think that apo A‑I may be a better indicator of the risk of coronary artery disease from the build-up of atheroma than the HDL test, but this has yet to be proven definitively.

Deficiencies in apo A‑I appear to correlate well with an increased risk of developing CHD and peripheral vascular disease. The routine use of apo A‑I is however not currently accepted as standard care in this country. Partly this is due to the fact that high HDL can also be associated with CHD and it is thought that you can have non-functional HDL i.e. lots of taxis driving about but not depositing cholesterol where they should. Therefore quantification of HDL is not enough on its own to truly indicate a person’s risk.

Common questions